Global Anti-nuclear Antibody Testing Market | Bussiness Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
Overview
The global Anti-nuclear Antibody Testing Market is estimated to grow at the highest CAGR in the forecast period 2021- 2028. The market is segmented into goods, disorders, methodologies, end-users, and regions in this analysis.
The Anti-nuclear Antibody Testing Market is divided into three types based on techniques: enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. Because of the growing uses of ANA in autoimmune disease testing and therapeutic medication level monitoring, the ELISA segment is predicted to account for the biggest proportion of this market.
Clinical laboratories, hospitals, POLs, and other end users are among the market's end-user groups. In 2016, the hospital sector is predicted to hold the greatest share of the worldwide ANA testing market. The fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, mostly due to simple access to reports and smooth logistics, has contributed to the segment's growth.
Growth Drivers
The Antinuclear Antibody Test Market is divided into three categories based on products: assay kits & reagents, systems, and software & services. In 2016, the market for assay kits and reagents is predicted to account for the highest share of the worldwide Anti-nuclear Antibody Testing Market. The increase in the number of reagent rental agreements and the rising prevalence of autoimmune illnesses are both contributing to this segment's growth.
Market Segmentation
Rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, scleroderma, and other disorders are the five key disease segments in the industry. Raynaud's syndrome, polymyositis, mixed connective tissue disease, drug-induced lupus, and autoimmune hepatitis are among the other disorders. Because of the rising incidence of rheumatoid arthritis, the rheumatoid arthritis category is predicted to account for the greatest market share.
The Anti-nuclear Antibody Testing Market is divided into three types based on techniques: enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. Because of the growing uses of ANA in autoimmune disease testing and therapeutic medication level monitoring, the ELISA segment is predicted to account for the biggest proportion of this market.
Clinical laboratories, hospitals, POLs, and other end users are among the market's end-user groups. In 2016, the hospital sector is predicted to hold the greatest share of the worldwide ANA testing market. The fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, mostly due to simple access to reports and smooth logistics, has contributed to the segment's growth.
Alere Inc. (US), Bio-Rad Laboratories, Inc., ERBA Diagnostics, Inc., Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc., Antibodies, Inc., EUROIMMUN AG, Immuno Concepts, Inova Diagnostics, and Zeus Scientific, Inc. are the major players in the antinuclear antibody test market.
Comments
Post a Comment